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Background—Urokinase-type plasminogen activator (uPA) has recently been implicated in the pathogenesis of
ischemia-reperfusion (I/R) injury. The underlying mechanisms remain largely unclear.
Methods and Results—Using in vivo microscopy on the mouse cremaster muscle, I/R-elicited firm adherence and
transmigration of neutrophils were found to be significantly diminished in uPA-deficient mice and in mice treated with
the uPA inhibitor WX-340, but not in uPA receptor (uPAR)–deficient mice. Interestingly, postischemic leukocyte
responses were significantly reduced on blockade of the integrin CD11b/Mac-1, which also serves as uPAR receptor.
Using a cell transfer technique, postischemic adherence and transmigration of wild-type leukocytes were significantly
decreased in uPA-deficient animals, whereas uPA-deficient leukocytes exhibited a selectively reduced transmigration in
wild-type animals. On I/R or stimulation with recombinant uPA, 90% of firmly adherent leukocytes colocalized with
CD31-immunoreactive endothelial junctions as detected by in vivo fluorescence microscopy. In a model of hepatic I/R,
treatment with WX-340 significantly attenuated postischemic neutrophil infiltration and tissue injury.
Conclusions—Our data suggest that endothelial uPA promotes intravascular adherence, whereas leukocyte uPA facilitates
the subsequent paracellular transmigration of neutrophils during I/R. This process is regulated via CD11b/Mac-1, and
does not require uPAR. Pharmacological blockade of uPA interferes with these events and effectively attenuates
postischemic tissue injury. (Circulation. 2011;124:1848-1859.)
Key Words: ischemia  leukocytes  plasminogen activators  reperfusion  urokinase
Ischemia-reperfusion (I/R) injury is considered to be themost common cause of organ dysfunction and failure after
myocardial infarction, hemorrhagic shock, and transplanta-
tion. Leukocyte infiltration of postischemic tissue is a key
event in the pathogenesis of I/R injury. In this multistep
cascade, a diversity of adhesion molecules, chemoattractants,
and proteases are involved, regulating intravascular rolling
and firm adherence as well as transendothelial migration of
leukocytes to the reperfused tissue.1–4
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Urokinase-type plasminogen activator (uPA) is a serine
protease that has been implicated in a variety of physiological
and pathophysiological processes. In this context, uPA is
known to activate extracellular matrix–degrading enzymes
and, through interaction with the urokinase receptor (uPAR;
CD87), uPA is thought to induce intracellular signaling
pathways, ultimately regulating cell adhesion and migration.5
Moreover, uPA mediates the conversion of plasminogen to
plasmin, which, in addition to its fibrinolytic properties, is
also able to degrade components of the ECM as well as to
activate intracellular signaling mechanisms.6
Plasminogen activators, such as recombinant uPA, are
therapeutically used for the activation of the fibrinolytic
system during thrombembolic events.7 Interestingly, how-
ever, endogenously released uPA has recently been impli-
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cated in the pathogenesis of I/R injury.8 The underlying
mechanisms remain largely unclear. In particular, the role of
uPA for each single step in the extravasation process of
leukocytes is not understood.
In addition to leukocyte infiltration, impaired microvascu-
lar barrier function is a detrimental consequence of I/R.
Previously, uPA has been demonstrated to be critically
involved in the regulation of microvascular permeability in
diabetic retinopathy.9 The functional relevance of this pro-
tease for the control of postischemic microvascular leakage
has not yet been explored.
Clinical trials are currently evaluating the curative poten-
tial of pharmacological serine protease inhibitors in cancer
therapies. The effect of these compounds on the prevention of
I/R injury has not yet been studied.
Therefore, the objective of our study was (1) to analyze the
functional relevance of uPA for the single steps of the
extravasation cascade of leukocytes as well as for the regu-
lation of microvascular permeability during I/R, (2) to char-
acterize the underlying mechanisms, and (3) to evaluate the
therapeutic potential of pharmacological uPA inhibition on
the prevention of postischemic tissue injury.
Here, we demonstrate that uPA mediates postischemic
neutrophil responses independently of uPAR but via the
integrin CD11b/Mac-1, which, in addition to its multiple
functions, has recently been shown to serve as receptor of
uPA. In this context, endothelial-presented uPA is thought to
promote intravascular firm adherence via its nonproteo-
lytic properties, whereas leukocyte uPA subsequently fa-
cilitates the paracellular transmigration of neutrophils to
the reperfused tissue. Concomitantly, postischemic micro-
vascular leakage is triggered by uPA in an uPAR-
dependent manner. Pharmacological inhibition of uPA
effectively interferes with these events and significantly
attenuates neutrophil infiltration, microvascular leakage,
and injury of the reperfused tissue.
Methods
Animals
Male C57BL/6 mice were purchased from Charles River (Sul-
zfeld, Germany). Male uPA-/- and uPAR-/- mice were generated
as described10,11 and backcrossed for 10 generations to the
C57BL/6 background. All experiments were performed with male
mice at the age of 10 to 20 weeks. Animals were housed under
conventional conditions with free access to food and water. All
experiments were performed according to German legislation for
the protection of animals.
M. Cremaster Assay
The surgical preparation of the cremaster muscle of anesthetized
mice (ketamine/xylazine) was performed as originally described by
Baez with minor modifications.12
In Vivo Microscopy
The setup for in vivo microscopy was centered around an Olympus
BX 50 upright microscope (Olympus Microscopy, Hamburg, Ger-
many) equipped for stroboscopic fluorescence epi-illumination mi-
croscopy. Microscopic images were obtained with Olympus water
immersion lenses (20/numeric aperture 0.5 and 10/numeric
aperture 0.3) and recorded with an analog black-and-white charge-
coupled device (CCD) video camera (Cohu 4920, Cohu, San Diego,
CA) and an analog video recorder (AG-7350-E, Panasonic, Tokyo,
Japan). Oblique illumination was obtained as described previously.13
Quantification of Leukocyte Kinetics and
Microhemodynamic Parameters
Off-line analysis of parameters describing the sequential steps of
leukocyte extravasation was performed by using the Cap-Image
image analysis software (Dr Zeintl, Heidelberg, Germany).13
Quantification of Fluorescent Leukocyte Responses
To investigate the contribution of leukocyte and nonleukocyte uPA
to postischemic leukocyte responses, a cell-transfer technique was
used as described previously.14
Hepatic I/R Injury
Warm ischemia of the left liver lobe was induced for 90 minutes by
reversible clamping of the supplying vessels as described
previously.15
Inhibitors and Antibodies
An Alexa Fluor 488-conjugated anti-CD31/PECAM-1 mAb (40 g
in 150 L of saline; intra-arterially (i.a.); BioLegend, San Diego,
CA) was used to delineate endothelial junctions. Recombinant
murine high–molecular-weight uPA as well as human uPA
(varying doses in 0.4 mL PBS; Molecular Innovations, Novi, MI)
was used to analyze the mechanisms underlying uPA-dependent
leukocyte responses. Murine uPA was titrated with murine
plasminogen activator inhibitor type 1 (PAI-1; Molecular Inno-
vations) or diisopropylfluorophosphate (DFP; Calbiochem,
Darmstadt, Germany) so that no proteolytic activity remained.
WX-340 (10 mg kg1 in 50 L saline; i.p.; WILEX, Munich,
Germany) is a competitive inhibitor of murine16 and human
uPA.17 Anti-CD11b/Mac-1 mAb, anti-CD54/ICAM-1 mAb, and
anti-CD102/ICAM-2 mAb (50 g in 150 L saline; i.a.; BioLegend)
were used to inhibit interactions with CD11b/Mac-1, CD54/ICAM-1
or CD102/ICAM-2. M25 (PRYQHIGLVAMFRQNTG; disrupts in-
teraction of CD11b/Mac-1 with uPAR18) and its scrambled peptide
scM25 (HQIPGAYRGVNQRFTML; 250 g in 150 L saline; i.a.)
were kindly provided by Dr G. Arnold (LAFUGA, Ludwig-
Maximilians-Universita¨t Mu¨nchen, Munich, Germany). SCH 79797
(25 g/kg body weight in 150 L saline; i.a.; Tocris Bioscience,
Ellisville, MO) was used to inhibit interactions with protease-acti-
vated receptor 1.
Experimental Protocols
For the analysis of postischemic leukocyte responses, 3 postcapillary
vessel segments in a central area of the spread out cremaster muscle
were randomly chosen. After having obtained baseline recordings of
leukocyte rolling, firm adhesion, and transmigration in all 3 vessel
segments, ischemia was induced by clamping all supplying vessels at
the base of the cremaster muscle using a vascular clamp (Martin,
Tuttlingen, Germany). In selected experiments, an anti-CD11b/Mac-1
mAB, the uPA inhibitor WX-340, or an isotype control antibody/drug
vehicle was applied 5 minutes before the onset of reperfusion. After 30
minutes of ischemia, the vascular clamp was removed and reperfu-
sion was restored for 160 minutes. Measurements were repeated at
60 and 120 minutes after onset of reperfusion.
For the analysis of uPA-dependent leukocyte responses, leukocyte
recruitment to the cremaster muscle was induced by intrascrotal
injection of recombinant murine uPA (0.02 g, 0.2 g, and 2.0 g
in 0.4 mL PBS). After 240 minutes, 5 vessel segments were
randomly chosen in a central area of the spread-out cremaster
muscle. In additional experiments, an anti-CD11b/Mac-1 mAb or an
isotype control antibody were applied before the intrascrotal injec-
tion of murine uPA, DFP-uPA, uPA-PAI-1 complex, or human uPA.
In further experiments, anti-CD54/ICAM-1 mAb, anti-CD102/
ICAM-2 mAb, SCH 79797, or isotype control antibody/drug vehicle
were applied before the intrascrotal injection of murine uPA.
After having obtained recordings of migration parameters, blood
flow velocity was determined. In selected experiments, FITC dextran
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was subsequently infused intra-arterially. for the analysis of micro-
vascular permeability (see Microvascular Permeability below). After
in vivo microscopy, tissue samples of the cremaster muscle were
taken for immunohistochemistry. Blood samples were collected by
cardiac puncture for the determination of systemic leukocyte counts
using a Coulter AcT Counter (Coulter Corp, Miami, FL). Anesthe-
tized animals were then euthanized by exsanguination.
For the analysis of postischemic tissue injury, warm ischemia of
the left liver lobe was induced for 90 minutes. Five minutes prior to
reperfusion, the uPA inhibitor WX-340 or drug vehicle were applied.
Tissue and blood samples were collected after 120 minutes of
reperfusion.
Microvascular Permeability
Analysis of microvascular permeability was performed as described
previously.19
Leukocyte Transmigration Routes
In separate experiments, assessment of leukocyte transmigration
routes was performed in the cremaster muscle as described previ-
ously with minor modifications.20
Confocal Microscopy
For the analysis of uPA expression, cremaster muscles were prepared as
described previously.19 After incubation with a primary rabbit anti-uPA
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and a
rat antimouse anti-CD62E/E-selectin antibody (Abcam, Cambridge,
UK), tissues were incubated with the secondary Alexa Fluor 488-linked
goat anti-rat or Alexa Fluor 546-linked goat anti-rabbit antibody
(Invitrogen, Carlsbad, CA). Immunostained tissues were mounted in
PermaFluor (Beckman Coulter, Fullerton, CA) on glass slides and
observed using a Leica SP5 confocal laser-scanning microscope (Leica
Microsystems, Wetzlar, Germany).
Statistics
Data analysis was performed with a statistical software package
(SigmaStat for Windows, Jandel Scientific, Erkrath, Germany). After
testing normality of data (using the Shapiro-Wilk test), the 1-way
ANOVA test followed by the Student-Newman-Keuls test (2
groups) or the t test (2 groups) was used for the estimation of
stochastic probability in intergroup comparisons. Mean values and
SEM are given. P values 0.05 were considered significant.
Results
Role of uPA and uPAR for Postischemic
Leukocyte Responses
In a first set of experiments, rolling, firm adherence, and
transendothelial migration of leukocytes were analyzed in the
mouse cremaster muscle by using in vivo transillumination
microscopy (Figure 1A). Surgical preparation of the cremas-
ter muscle induced leukocyte rolling in postcapillary venules.
At baseline conditions before induction of ischemia as well as
after 60 and 120 minutes of reperfusion, no significant
differences were detected in numbers of rolling leukocytes
among all experimental groups (data not shown).
Before ischemia, the number of leukocytes attached to the
inner vessel wall of postcapillary venules was low and did not
differ among experimental groups (Figure 1B). In contrast,
after 30 minutes of ischemia and 120 minutes of reperfusion,
there was a significant elevation in numbers of firmly
adherent leukocytes (14.20.7/104 m2) compared with
sham-operated animals (4.81.0/104 m2). This elevation
was significantly diminished in uPA-deficient (8.60.9/104
m2) but not in uPAR-deficient animals (18.92.4/104 m2).
At baseline conditions, only few transmigrated leukocytes
were found within the perivenular tissue (Figure 1C). In
contrast, the number of transmigrated leukocytes was signif-
icantly increased after 120 minutes of reperfusion (25.92.0/
104 m2) compared with sham-operated mice (7.31.3/104
m2). This increase was significantly attenuated in uPA-
deficient (17.81.9/104m2) but not in uPAR-deficient mice
(27.71.5/104 m2). Similar results for postischemic rolling,
firm adherence, and transmigration of leukocytes were ob-
tained already after 60 minutes of reperfusion.
In a further set of experiments, the functional relevance of
interaction of uPAR with CD11b/Mac-1 for I/R-elicited
leukocyte recruitment was evaluated. We found that admin-
istration of M25 (which disrupts interaction of uPAR with
CD11b/Mac-1) did not significantly alter postischemic leu-
kocyte responses (online-only Data Supplement Figure I).
Role of CD11b/Mac-1 for Postischemic
Leukocyte Responses
In further experiments, the role of the integrin CD11b/Mac-1,
which, in addition to its role as adhesion molecule and
complement receptor, has recently been identified as a
receptor of uPA, for postischemic leukocyte responses was
analyzed. No significant differences were observed in num-
bers of rolling leukocytes among experimental groups at all
time points of measurement (data not shown). At baseline
conditions, the number of firmly adherent (Figure 1D) and
transmigrated leukocytes (Figure 1E) was low and did not
differ among experimental groups. As described above, after
30 minutes of ischemia and 60 as well as 120 minutes of
reperfusion, there was a significant elevation in the number of
firmly adherent (20.91.2/104 m2) and (subsequently)
transmigrated (25.80.9/104 m2) leukocytes compared to
sham-operated animals (4.81.0/104 m2; 7.31.3/104
m2). This elevation was almost completely abrogated in
animals treated with a blocking anti-CD11b/Mac-1 mAb
(4.20.7/104 m2; 13.51.3/104 m2).
Effect of uPA on Leukocyte Rolling, Firm
Adherence, and Transmigration
To directly investigate the effect of uPA on leukocyte rolling,
firm adherence, and transmigration, an intrascrotal injection
of different concentrations of recombinant murine uPA (0.02,
0.2, or 2.0 g) was performed. In response to uPA, no
significant differences were observed in numbers of rolling
leukocytes among all experimental groups (Figure 2A). In
control animals receiving an intrascrotal injection of PBS
only, few firmly adherent (4.70.9/104 m2) and transmi-
grated (5.70.2/104 m2) leukocytes were found. In contrast,
after stimulation with uPA, there was a dose-dependent
increase in numbers of firmly adherent (10.33.2/104 m2;
15.01.9/104 m2; 22.27.1/104 m2; Figure 2B) and trans-
migrated leukocytes (8.81.5/104 m2; 10.41.6/104 m2;
18.23.4/104 m2; Figure 2C). Because the highest dose of
uPA applied (2.0 g) induced a significant increase in
numbers of firmly adherent as well as transmigrated leuko-
cytes, this dose was used in further experiments. In this
context, the role of CD11b/Mac-1 for uPA-dependent leuko-
cyte responses was analyzed. On blockade of CD11b/Mac-1,
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leukocyte rolling was not significantly altered (Figure 2D),
whereas firm adherence (5.71.7/104 m2; Figure 2E) and
(subsequent) transmigration (9.60.6/104 m2; Figure 2F) of
leukocytes were almost completely abolished.
Moreover, stimulation with murine DFP-uPA or with
uPA-PAI-1 complex, in which the proteolytic activity of uPA
is inhibited, as well as with human uPA, which does not
interact with murine uPAR, induced a significant elevation in
numbers of firmly adherent (20.91.3/104 m2; 20.51.5/
104 m2; 20.92.8/104 m2; Figure 2H) and transmigrated
(24.41.3/104 m2; 25.02.3/104 m2; 23.11.6/104 m2)
leukocytes (Figure 2I) compared to controls (4.70.3/104
m2; 5.20.5/104 m2) but did not significantly alter leuko-
cyte rolling (Figure 2G). Although DFP-uPA–mediated leu-
kocyte recruitment was almost completely abolished in ani-
mals receiving an anti-CD11b/Mac-1 antibody, blockade of
CD11b/Mac-1 only partially reduced leukocyte responses
elicited by uPA-PAI-1 complex or human uPA. In a further
set of experiments, uPA-elicited leukocyte firm adherence
and (subsequent) transmigration were significantly reduced
on blockade of the potential CD11b/Mac-1 binding partners
CD54/ICAM-1 or CD102/ICAM-2 (online-only Data Supple-
ment Figure II) whereas leukocyte rolling was not affected
(data not shown). Finally, blockade of protease-activated
receptor-1 with compound SCH 79797 did not alter uPA-
elicited leukocyte responses (online-only Data Supplement
Figure III).
Role of Leukocyte Versus Nonleukocyte uPA for
Postischemic Leukocyte Responses
Using immunostaining and confocal microscopy, postis-
chemic expression of uPA was primarily detected on
Figure 1. Role of uPA for postischemic leukocyte recruitment. Representative in vivo transillumination microscopy images of postcapil-
lary venules in WT, uPA, and uPAR-deficient mice undergoing I/R (A; scale bar: 20 m). Leukocyte firm adherence and transmigration
were quantified in postcapillary venules of the cremaster muscle by using in vivo transillumination microscopy. Panels show results for
sham-operated WT mice and for WT, uPA-deficient, and uPAR-deficient mice (B and C), as well as for WT mice treated with a blocking
anti-CD11b/Mac-1 mAb or isotype control (D and E) undergoing I/R (meanSEM for n6 per group; #P0.05 versus sham; *P0.05
versus WT/isotype control). WT indicates wild type; uPA-/-, urokinase-type plasminogen activator deficient; and uPAR-/-, urokinase-
type plasminogen activator receptor deficient.
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cremasteric microvessels as well as on transmigrated
leukocytes (Figure 3A). Expression of uPA by the respec-
tive cellular sources was confirmed in isolated endothelial
cells and neutrophils using flow cytometry (online-only
Data Supplement Figure IV).
To further evaluate the relative contribution of leukocyte
versus nonleukocyte uPA for postischemic leukocyte responses,
a cell-transfer technique was applied. In postcapillary venules of
the reperfused cremaster muscle, the number of adherent
(0.210.06/high power field; Figure 3B) and transmigrated
(0.170.06/HPF; Figure 3C) wild-type (WT) donor cells was
significantly diminished in uPA-deficient recipient animals com-
pared with WT animals receiving cells from WT donors
(0.570.1/HPF; 0.400.1/HPF). In contrast, postischemic ad-
herence (0.70.1/HPF) of uPA-deficient donor cells was not
significantly altered in WT recipients whereas their transmigra-
tion (0.20.01/HPF) was significantly reduced.
Postischemic Transmigration Routes of Leukocytes
Using in vivo immunostaining of endothelial junctions by
using an Alexa Fluor 488-antibody directed against the
junctional molecule CD31/PECAM-1, a diamond-shaped
profile of endothelial junctions in cremasteric arterioles was
found, whereas endothelial junctions in postcapillary venules
exhibited a cobblestone-like profile (Figure 4A). Leukocytes
are thought to either squeeze between endothelial junctions
(paracellular transmigration route) or to directly penetrate
endothelial cells (transcellular transmigration route) during
their transendothelial migration from postcapillary venules.
To assess the transmigration route leukocytes use during
I/R, the relative localization of firmly adherent leukocytes
to endothelial junctions was determined by combining
transillumination and fluorescence in vivo microscopy
(Figure 4B). On I/R (95.11.1%) as well as after stimu-
lation with uPA (94.00.9%), 90% of firmly adherent
leukocytes colocalized with endothelial junctions of post-
capillary venules (Figure 4C).
Phenotyping Transmigrated Leukocytes
To identify the phenotype of transmigrated leukocytes, im-
munostaining for CD45 (common leukocyte antigen), Ly-6G
Figure 2. Effect of uPA on rolling, firm adherence, and transmigration of leukocytes. Leukocyte rolling (A), firm adherence (B), and
transmigration (C) were quantified in postcapillary venules of the cremaster muscle after 240 minutes of intrascrotal stimulation with
varying concentrations of murine uPA using in vivo transillumination microscopy (meanSEM for n3 per group; #P0.05 versus
unstimulated control). In further experiments, the role of the alternative uPA receptor CD11b/Mac-1 for rolling, firm adherence, and
transmigration of leukocytes was analyzed. Panels show results for unstimulated WT mice receiving an intrascrotal injection of PBS as
well as for WT mice treated with a blocking anti-CD11b/Mac-1 mAb or isotype control undergoing stimulation with murine uPA (D, E,
and F), murine DFP-uPA, murine uPA-PAI-1 complex, or human uPA (G, H, and I; meanSEM for n4–6 per group; #P0.05 versus
unstimulated; *P0.05 versus isotype control). uPA indicates urokinase-type plasminogen activator; WT, wild type; DFP, diisopropyl-
fluorophosphate; PAI, plasminogen activator inhibitor; and h, human.
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(neutrophils), and F4/80 (monocytes/macrophages) of crem-
asteric tissue samples was performed. In response to I/R as
well as on stimulation with uPA, 80% of transmigrated
leukocytes were positive for Ly-6G and 10% to 20% of
transmigrated leukocytes were positive for F4/80, respec-
tively (data not shown).
Role of uPA and uPAR for Postischemic
Microvascular Leakage
As a measure of microvascular permeability, leakage of the
macromolecule FITC dextran into the perivascular tissue was
determined by using fluorescence in vivo microscopy on the
cremaster muscle (Figure 5A). In response to I/R (30/150
minutes), there was a significant increase in the leakage of
FITC dextran (398.554.1) compared with sham-operated
mice (145.420.4; Figure 5B). Interestingly, this increase
was completely abolished in both uPA- (201.723.0) and
uPAR-deficient (180.226.9) mice.
Effect of WX-340 on Postischemic Leukocyte
Responses and Microvascular Leakage
To analyze the effect of the uPA inhibitor WX-340 on
postischemic leukocyte responses and microvascular leakage,
an additional set of experiments was performed. In response
to I/R (30/120 minutes), there was a significant increase in
numbers of firmly adherent (13.81.7/104 m2; Figure 6A)
and transmigrated (28.93.2/104 m2; Figure 6B) leukocytes
compared with sham-operated animals (4.81.0/104 m2;
7.31.3/104 m2). This increase was significantly diminished
in animals treated with WX-340 (9.41.5/104 m2;
18.02.0/104 m2). Moreover, I/R (30/150 minutes) caused a
significant elevation in the leakage of FITC dextran
(471.773.8) compared with sham-operated controls
(145.420.4; Figure 6C). This elevation was significantly
reduced in mice treated with WX-340 (124.721.2).
Effect of WX-340 on Postischemic Leukocyte
Infiltration and Tissue Injury of the Liver
In a model of hepatic I/R, the effect of the uPA inhibitor
WX-340 on postischemic leukocyte infiltration as well as on
tissue injury was evaluated. On I/R of the liver, a significant
increase in numbers of leukocytes (27.93.3/HPF; 70%
Ly-6G neutrophils) infiltrating the postischemic liver tissue
was observed compared with sham-operated animals
(6.70.8/HPF; Figure 6D). This increase was significantly
diminished in animals treated with the uPA inhibitor WX-340
(12.21.5/HPF).
As a measure of hepatic tissue injury, serum levels of
aspartate aminotransferase and alanine aminotransferase were
determined. I/R induced a significant elevation in the serum
levels of aspartate aminotransferase and alanine aminotrans-
ferase (5015.4602.3 U/L; 10623.41241.5 U/L; Figure 6E)
compared with sham-operated animals (329.856.6 U/L;
97.38.0 U/L). This elevation was significantly attenuated in
animals treated with WX-340 (3010.5441.5 U/L;
6088.9959.5 U/L). It is worth noting that treatment with
WX-340 neither induced leukocyte infiltration of the liver,
nor an elevation of serum transaminases in sham-operated
animals.
Figure 3. Role of leukocyte versus non-
leukocyte uPA for postischemic leukocyte
responses. Representative confocal
microscopy images of a postcapillary
venule in the postischemic cremaster
muscle immunostained for uPA (green)
and the endothelial cell marker CD62E/E-
selectin (red; scale bar: 25 m; A). Adher-
ence (B) and transmigration (C) of calcein
AM-labeled bone marrow leukocytes were
quantified in the cremaster muscle after
30 minutes of ischemia and 120 minutes
of reperfusion using in vivo fluorescence
microscopy. Panels show results for WT
mice receiving leukocytes from WT or
uPA-deficient donors as well as for uPA-
deficient mice receiving leukocytes from
WT donors (meanSEM for n5 per
group; *P0.05 versus WT3WT). uPA
indicates urokinase-type plasminogen ac-
tivator; HPF, high power field; WT, wild
type; and uPA-/-, urokinase-type plasmin-
ogen activator deficient.
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Plasma Activity of uPA
In a final set of experiments, uPA activity was measured in
plasma samples by zymography. In response to I/R of the right
cremaster muscle, uPA activity was not significantly altered
compared with sham-operated controls. Moreover, treatment
with heparin, which—besides its anticoagulative properties and
its inhibitory effect on protein binding to endothelial cells—is
thought to exert a broad range of further effects (eg, inhibition of
protease activity as well as of ligand binding to adhesion molecules
such as CD11b/Mac-1 and selectins), did not affect postischemic
uPA activity levels (online-only Data Supplement Figure V).
Systemic Leukocyte Counts and
Microhemodynamic Parameters
To assure intergroup comparability, quantification of inner
vessel diameters, blood flow velocities, and shear rates of
Figure 4. Leukocyte transmigration
routes. Representative in vivo microscopy
image of an arteriole (A) and of a post-
capillary venule (V) in the cremaster mus-
cle immunostained for CD31/PECAM-1
(A; scale bar: 20 m). Arrows indicate
firmly adherent leukocytes colocalizing
with endothelial junctions of a postcapil-
lary venule in the postischemic cremaster
muscle (B; scale bar: 20 m). C, Results
for the relative localization of firmly adher-
ent leukocytes to endothelial junctions
(green) in postcapillary venules of WT
mice undergoing I/R or stimulation with
recombinant murine uPA (meanSEM for
n3 per group). A indicates arteriole; V,
venule; I/R, ischemia-reperfusion; and
uPA, urokinase-type plasminogen
activator.
Figure 5. Role of uPA for the regulation
of postischemic microvascular permeabil-
ity. As a measure of microvascular per-
meability, leakage of FITC dextran into
the perivascular space was quantified
using in vivo fluorescence microscopy (A;
scale bar: 100 m). B, Results for sham-
operated WT mice as well as for WT,
uPA-deficient, and uPAR-deficient mice
undergoing I/R (meanSEM for n6 per
group; #P0.05 versus sham; *P0.05
versus WT). WT indicates wild type;
uPA-/-, urokinase-type plasminogen acti-
vator deficient; and uPAR-/-, urokinase-
type plasminogen activator receptor
deficient.
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analyzed postcapillary venules as well as systemic leukocyte
counts was performed (Table; online-only Data Supplement
Table I). On stimulation with uPA, DFP-uPA, or uPA-PAI-1
complex, shear rates as well as systemic leukocyte counts
were significantly altered compared to PBS-treated control
animals. Among all other experimental groups, no significant
differences were detected.
Discussion
Immediate restoration of organ perfusion is the primary goal
after myocardial infarction, hemorrhagic shock, and trans-
plantation.7 Reperfusion of postischemic tissue, however,
inevitably induces secondary tissue damage as neutrophils
accumulate within the reperfused microvasculature and com-
promise restoration of the blood flow. In addition, subse-
quently transmigrating neutrophils release reactive oxygen
species, cytokines, and proteases, affecting microvascular
integrity as well as promoting the postischemic tissue in-
jury.1–4 Interestingly, transmigrated neutrophils also contrib-
ute to tissue healing and regeneration, collectively emphasiz-
ing neutrophil recruitment as a hallmark in the pathogenesis
of I/R injury.15,21
Plasminogen activators such as recombinant uPA are
clinically used after thrombembolic events in order to pro-
Figure 6. Effect of WX-340 on postischemic leukocyte responses, microvascular leakage, and tissue injury. Leukocyte firm adherence
(A) and transmigration (B) as well as FITC-dextran leakage (C) were quantified in postcapillary venules of the cremaster muscle under-
going I/R by using in vivo microscopy. Panels show results for sham-operated WT mice as well as for WT mice treated with the uPA
inhibitor WX-340 or vehicle undergoing I/R (meanSEM for n6 per group; #P0.05 versus sham; *P0.05 versus WT). In a model of
hepatic I/R injury, transmigrated CD45 cells (representing leukocytes) in paraffin-embedded tissue sections of the liver (D) as well as
serum levels of aspartate aminotransferase and alanine aminotransferase (E) were determined. Panels show results for sham-operated
WT mice treated with WX-340 or vehicle as well as for WT mice treated with WX-340 or vehicle undergoing I/R (meanSEM for n6
per group; #P0.05 versus shamvehicle; *P0.05 versus I/Rvehicle; §P0.05 versus shamWX-340). WT indicates wild type; HPF,
high power field; I/R, ischemia-reperfusion; AST, aspartate aminotransferase; and ALT, alanine aminotransferase.
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mote reperfusion of the affected tissue by enhancing fibrino-
lysis.7 Recently, however, endogenously generated uPA has
been implicated in the pathogenesis of I/R injury.8 The
underlying mechanisms remain largely unclear.
Using near-infrared transillumination in vivo microscopy,
the single steps of the extravasation cascade of leukocytes
were analyzed in postcapillary venules of the mouse cremas-
ter muscle. In our experiments, neutrophil infiltration of the
postischemic tissue was found to be significantly reduced in
animals lacking uPA. These results are in line with previous
observations: Leukocyte extravasation has been reported to
be significantly attenuated in uPA-deficient animals during
different inflammatory conditions.5,22 In this context, pro-
teases including uPA were originally thought to selectively
facilitate neutrophil transmigration by cleaving endothelial
junctions as well as by proteolytically degrading the perive-
nular basement membrane. In contrast, our in vivo micros-
copy data clearly demonstrate that in uPA-deficient animals
postischemic neutrophil extravasation is inhibited already on
the level of intravascular firm adherence. A possible expla-
nation for these observations might be that uPA, in addition to
its classic role as a proteolytic enzyme, might serve as an
inflammatory mediator.
To prove this hypothesis, we directly investigated the
effect of uPA on rolling, firm adherence, and transmigration
of leukocytes. Our data demonstrate that stimulation with
recombinant murine uPA induces a dose-dependent increase
in numbers of firmly adherent and (subsequently) transmi-
grated neutrophils whereas leukocyte rolling remains unal-
tered. In addition, comparable leukocyte responses were
measured on stimulation with DFP-uPA or uPA-PAI-1 com-
plex, in which the proteolytic activity of uPA is inhibited.
These findings extend previous observations given that intra-
articular injection of uPA has been reported to cause leuko-
cyte infiltration of the synovial tissue23 and, moreover,
suggest that uPA might act as a neutrophil attractant in the
postischemic inflammatory response. In this context, it is
interesting that postischemic expression of uPA was primar-
ily detected on cremasteric microvessels. Because glycosami-
noglycans have recently been shown to serve as binding
partners of uPA,24 these molecules might present uPA—in a
manner similar to that of classic chemokines—on the luminal
Table. Intergroup Comparability. Quantification of Inner Vessel Diameters, Blood Flow Velocities, Shear Rates of Analyzed
Postcapillary Venules, and Systemic Leukocyte Counts
Stimulus Strain Treatment
Inner
Diameter, m
Vmean,
mm/s
Shear Rate,
Seconds1
Systemic
Leukocyte, Counts 103 L1
Sham WT 26.31.2 1.40.1 2136.2148.8 3.70.5
I/R WT 26.00.7 1.40.1 2028.3139.8 3.60.8
I/R uPA-/- 25.71.4 1.30.1 2061.2102.7 4.10.5
I/R uPAR-/- 25.21.1 1.40.1 2179.8119.3 4.00.8
I/R WT IgG2b 25.10.6 1.40.1 2207.554.2 4.80.5
I/R WT Anti-CD11b
mAb
26.21.7 1.20.1 1804.4149.7 4.00.7
I/R WT Vehicle 25.80.3 1.30.1 1948.531.9 4.70.7
I/R WT WX-340 26.20.7 1.30.1 1897.783.8 3.61.1
control (PBS) WT 24.71.0 1.60.1 2522.8142.2 6.31.2
uPA (0.02 g) WT 25.41.0 1.60.1 2533.4101.9 4.41.3
uPA (0.2 g) WT 24.01.5 1.70.1 2755.533.4 7.20.6
uPA (2.0 g) WT 24.50.9 1.50.1 2373.9256.1 4.91.3
control (PBS) WT 24.20.5 1.50.1 2427.5133.4 6.20.7
uPA (2.0 g) WT IgG2b 26.40.6 1.30.1 1903.899.1* 5.61.0
uPA (2.0 g) WT Anti-CD11b
mAb
26.01.1 1.40.1 2057.244.6* 5.50.4
control (PBS) WT 23.90.8 1.40.1 2302.8156.9 6.40.9
DFP-uPA (2.0 g) WT IgG2b 25.20.6 1.20.1 1828.226.1* 3.30.3*
DFP-uPA (2.0 g) WT Anti-CD11b
mAb
21.91.6 1.20.1 2231.8199.3 3.80.5*
uPA-PAI-1 (4.0 g) WT IgG2b 24.20.8 1.20.1 1901.168.7* 3.80.2*
UPA-PAI-1 (4.0 g) WT Anti-CD11b
mAb
25.20.4 1.10.1 1780.780.2* 3.10.8*
h-uPA (2.0 g) WT IgG2b 25.40.8 1.10.1 1743.2104.6 4.50.8*
h-uPA (2.0 g) WT Anti-CD11b
mAb
25.10.7 1.10.1 1776.552.4 4.30.4
WT indicates wild type; I/R, ischemia-reperfusion; uPA-/-, urokinase-type plasminogen activator deficient; uPAR-/-, urokinase-type plasminogen activator receptor
deficient; IgG, immunoglobulin G; uPA, urokinase-type plasminogen activator; DFP, diisopropylfluorophosphate; PAI-1, plasminogen activator inhibitor type 1; and
h-uPA, human urokinase-type plasminogen activator.
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surface of endothelial cells. It is worth noting that uPA has
also been detected on the surface of transmigrated leukocytes.
According to previous reports, uPA is stored in primary
granules of unstimulated neutrophils and rapidly translocated
to the cell surface on cell activation.25 The relative contribu-
tion of leukocyte and nonleukocyte uPA to the leukocyte
recruitment process, however, is still unknown. In the present
study, we demonstrate that leukocyte and nonleukocyte uPA
cooperate during leukocyte extravasation. By using a cell-
transfer technique, we found that nonleukocyte uPA mediates
leukocyte intravascular adherence, whereas leukocyte uPA se-
lectively promotes the transendothelial migration of these in-
flammatory cells to postischemic tissue. These data lead us to the
conclusion that uPA presented on the luminal surface of endo-
thelial cells interacts with its receptor(s) on rolling leukocytes,
which in turn further activates these inflammatory cells and
promotes their firm adherence to the endothelium. Subsequently,
leukocyte uPA is engaged, facilitating the transendothelial mi-
gration of leukocytes to the postischemic tissue.
In this process, intravascularly adherent leukocytes might
either squeeze between adjacent endothelial cells (paracellu-
lar transmigration route) or directly penetrate endothelial
cells by using the transcellular transmigration route. Here, we
demonstrate that in the early reperfusion phase as well as in
response to uPA, 90% of firmly adherent leukocytes
colocalize with endothelial junctions of postcapillary venules.
Our findings suggest that neutrophils predominantly take the
paracellular transmigration route to extravasate to the postis-
chemic tissue and extend recently published observations26
by demonstrating that uPA is an important mediator in this
context.
Following previous in vitro data, uPA is supposed to
interact with uPAR, which has been demonstrated to modu-
late leukocyte-endothelial cell interactions by initiating a
variety of intracellular signaling pathways.5 Surprisingly,
deficiency of uPAR did not alter postischemic transmigration
of neutrophils, indicating that uPA mediates neutrophil infil-
tration of the reperfused tissue independently of this protein.
These findings are in agreement with previous observations,
because uPA-dependent monocyte recruitment did not re-
quire uPAR in experimental arteriogenesis.27 In addition, it
has been shown that uPA-uPAR interactions are dispensable
for other functions of uPA.28 In animal models of peritonitis29
or pneumonia,30 however, uPAR has been reported to be
critically involved in neutrophil migration, collectively sug-
gesting a stimulus- and/or tissue-specific engagement of this
receptor.
Interestingly, recent in vitro studies identified the 2-
integrin CD11b/Mac-1, which also serves as complement
receptor and as adhesion molecule, as another receptor of
uPA.31 In our experiments, we show that postischemic firm
adherence and (subsequent) transmigration of neutrophils
were significantly reduced on blockade of CD11b/Mac-1.
Furthermore, we found that uPA-elicited neutrophil responses
are almost completely dependent on CD11/Mac-1. Conse-
quently, these results indicate that uPA mediates neutrophil
recruitment to reperfused tissue via CD11b/Mac-1 and inde-
pendently of uPAR. This hypothesis is further supported by
our data because (1) human uPA, which does not interact with
murine uPAR, was able to induce significant CD11b/Mac-1-
dependent leukocyte responses and (2) administration of
M25, a peptide disrupting interaction of CD11b/Mac-1 with
uPAR (which has been reported to be functionally relevant
for cell migration32,33) did not significantly alter postischemic
leukocyte recruitment. In this context, however, it cannot
clearly be answered whether CD11b/Mac-1 serves as uPA
receptor or whether this integrin also mediates uPA-
dependent neutrophil responses via its other functional prop-
erties. Moreover, it can also not clearly be stated to what
extent uPA directly31 or indirectly (eg, by induction of
release/production of inflammatory mediators23) promotes
the migration of neutrophils to postischemic tissue.
In addition to leukocyte recruitment, microvascular leak-
age is a key event in the pathogenesis of I/R injury. Using in
vivo fluorescence microscopy, I/R-elicited leakage of FITC
dextran was found to be significantly attenuated in both uPA-
and uPAR-deficient animals. These findings confirm recent
observations that pharmacological blockade of uPA-uPAR
interaction significantly reduced microvascular leakage in the
retina of diabetic mice.9 In this context, interaction of uPA
with endothelial uPAR is thought to induce retraction of
endothelial cells,34 ultimately promoting the postischemic
microvascular leakage.
Clinical trials are currently evaluating the curative poten-
tial of serine protease inhibitors in cancer. The effect of these
Figure 7. Schematic diagram on the involvement
of uPA in the postischemic inflammatory response.
Urokinase-type plasminogen activator is thought to
mediate postischemic firm adherence and paracel-
lular transendothelial migration of neutrophils via
CD11b/Mac-1 and independently of uPAR. In this
context, endothelial-presented uPA is thought to
promote leukocyte firm adherence whereas leuko-
cyte uPA is thought to facilitate the subsequent
paracellular transmigration of neutrophils to the
reperfused tissue. Concomitantly, postischemic
microvascular leakage is triggered by uPA in a
uPAR-dependent manner. L indicates leukocyte;
EC, endothelial cells; uPA, urokinase-type plasmin-
ogen activator; and uPAR, urokinase-type plasmin-
ogen activator receptor.
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drugs on the prevention of I/R injury, however, has not yet
been studied. Our experimental data reveal that WX-340, a
novel highly selective uPA inhibitor, effectively diminishes
intravascular accumulation and (subsequent) transmigration
of neutrophils to the reperfused tissue as well as I/R-elicited
leakage of FITC dextran, collectively confirming our previ-
ous findings in uPA-deficient animals.
To further evaluate the therapeutic potential of the uPA
inhibitor in I/R injury, we employed a different experimental
model. On experimental I/R injury of the liver, postischemic
levels of serum transaminases were found to be dramatically
increased compared with sham-operated controls. Treatment
with WX-340, however, significantly attenuated the I/R-
elicited increase of serum aspartate aminotransferase and
alanine aminotransferase. These effects were accompanied by
significantly diminished neutrophil infiltration of the post-
ischemic liver. Consequently, pharmacological blockade
of uPA is thought to interfere with uPA-elicited neutrophil
recruitment in the early reperfusion phase, which, in turn,
effectively ameliorates tissue injury of the reperfused liver.
These findings are in line with recent observations, given
that protection of the postischemic cerebral microvascu-
lature by moderate hypothermia was associated with re-
duced tissue activity of uPA.8 Notably, expression of uPA
was found to be down-regulated on renal I/R, and uPA
deficiency (but not uPAR deficiency) did not affect post-
ischemic proteinuria,35,36 suggesting a tissue-specific in-
volvement of uPA and uPAR in the pathogenesis of I/R
injury. Moreover, it is worth to be noted that pharmaco-
logical blockade of endogenous plasminogen activation
might potentially exert antifibrinolytic side effects, which
might be fatal in situations such as myocardial infarction.
Because endogenous fibrinolysis is known to be largely
dependent on the plasminogen activating action of endog-
enous tissue-plasminogen activator10 and clinical trials did
not provide any evidence about prothrombotic side effects
of uPA inhibitors,37 targeting endogenously released uPA
might emerge as a feasible strategy for the prevention of
I/R injury.
In conclusion, our data demonstrate that uPA mediates
postischemic firm adherence and paracellular transendotheli-
al migration of neutrophils via CD11b/Mac-1 and indepen-
dently of uPAR. In this context, endothelial-presented uPA is
thought to promote leukocyte firm adherence via its nonpro-
teolytic properties whereas leukocyte uPA is thought to
facilitate the subsequent paracellular transmigration of neu-
trophils to the reperfused tissue. Concomitantly, postischemic
microvascular leakage is triggered by uPA in a uPAR-
dependent manner (Figure 7). Pharmacological inhibition of
uPA interferes with these inflammatory events and attenuates
postischemic neutrophil responses, microvascular leakage,
and tissue injury. These findings provide novel insights into
the pathogenesis of I/R injury and highlight uPA as a
promising therapeutic target for the prevention of postische-
mic tissue injury.
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CLINICAL PERSPECTIVE
Ischemia-reperfusion is still the most common cause for organ dysfunction and failure after myocardial infarction,
hemorrhagic shock, and transplantation. Neutrophil recruitment to the reperfused tissue as well as postischemic
microvascular leakage are critical for the pathogenesis of ischemia-reperfusion injury. Although plasminogen activators
such as recombinant urokinase-type plasminogen activator (uPA) are used therapeutically for the activation of the
fibrinolytic system in thrombembolic events, endogenously produced uPA has recently been implicated in the progression
of ischemia-reperfusion injury. The underlying mechanisms remain poorly understood. In the present study, we found that
endogenous uPA promotes intravascular accumulation and paracellular transmigration of neutrophils to the reperfused
tissue independently of the uPA receptor via the integrin CD11b/Mac-1, which serves as an alternative receptor of uPA.
Endothelial-presented uPA is thought to promote leukocyte intravascular adherence via its nonproteolytic properties
whereas leukocyte uPA is thought to trigger the subsequent paracellular transmigration of neutrophils. We further show that
postischemic microvascular leakage is mediated by uPA in a uPA receptor–dependent manner. Pharmacological inhibition
of uPA interferes with these inflammatory events and attenuates postischemic neutrophil responses, microvascular leakage,
and tissue injury. Because fibrinolysis is known to be largely dependent on the plasminogen-activating action of
endogenous tissue-plasminogen activator and clinical trials did not provide any evidence of pro-thrombotic side effects
relative to uPA inhibitors, pharmacological blockade of endogenously released uPA might emerge as a feasible strategy
for the prevention of ischemia-reperfusion injury.
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